A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

NCT03138499 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped Insufficient enrollment.

Conditions

Hodgkin's Disease

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Brentuximab vedotin

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]
[object Object]